Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Profit After Tax (2019 - 2025)

Historic Profit After Tax for Strata Critical Medical (SRTA) over the last 7 years, with Q3 2025 value amounting to $57.4 million.

  • Strata Critical Medical's Profit After Tax rose 112036.61% to $57.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 17326.04%. This contributed to the annual value of -$27.3 million for FY2024, which is 5130.36% up from last year.
  • Per Strata Critical Medical's latest filing, its Profit After Tax stood at $57.4 million for Q3 2025, which was up 112036.61% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Strata Critical Medical's Profit After Tax ranged from a high of $57.4 million in Q3 2025 and a low of -$33.9 million during Q4 2023
  • Over the past 5 years, Strata Critical Medical's median Profit After Tax value was -$9.2 million (recorded in 2021), while the average stood at -$5.9 million.
  • As far as peak fluctuations go, Strata Critical Medical's Profit After Tax tumbled by 906978.68% in 2021, and later surged by 112036.61% in 2025.
  • Strata Critical Medical's Profit After Tax (Quarter) stood at $772000.0 in 2021, then tumbled by 3631.09% to -$27.3 million in 2022, then fell by 24.51% to -$33.9 million in 2023, then surged by 71.15% to -$9.8 million in 2024, then skyrocketed by 686.3% to $57.4 million in 2025.
  • Its Profit After Tax was $57.4 million in Q3 2025, compared to -$3.7 million in Q2 2025 and -$3.5 million in Q1 2025.